Metabolex Initiates Phase II/III Trial of Insulin Sensitizer
Posted on: Monday, 12 June 2006, 15:00 CDT
Metabolex has initiated a phase II/III trial of its lead product candidate, metaglidasen, in patients with type 2 diabetes.
A novel insulin sensitizer, metaglidasen has been shown in a previously conducted phase II trial in patients with diabetes to be well tolerated and to lower blood glucose, triglycerides and uric acid levels without causing any increase in weight gain or edema, the common side effects of the currently marketed insulin sensitizers from the thiazolidinedione (TZD) class.
"Previous clinical trial findings suggest that metaglidasen is effective in controlling blood glucose levels, with a promising side effect profile. We believe metaglidasen has the potential to markedly improve the standard of care for patients with type 2 diabetes," said Dr Harold Van Wart, president and CEO of Metabolex.
The newly initiated trial will compare 200, 400 and 600mg daily doses of metaglidasen with 30mg of the TZD Actos in approximately 400 patients with type 2 diabetes taking concomitant insulin.
Source: Datamonitor
Related Articles
- PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2
- Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial
- Epidemics of Both Type 1 Diabetes (Insulin Dependent) and Type 2 Diabetes (Obesity Related) Are Linked to Immunization
- Speedel Stops Current SPP301 Phase III Trial in Diabetic Kidney Disease in the Interests of Patient Safety; Data to Be Analysed for Potential New Clinical Trials
- CVAC Systems and TempusClinic Partner to Study the Potential Value of The CVAC Process in Managing and Treating Diabetes, Insulin Resistance, and Metabolic Syndrome
- Avandia(R) (Rosiglitazone Maleate) Reduced Risk of Progression From Pre-Diabetes To Type 2 Diabetes By 62 Percent in Largest Completed Diabetes Prevention Trial
- Metabolex Initiates Phase 2/3 Trial of Metaglidasen in Patients With Type 2 Diabetes
- CVBT Announces It Will Begin U.S. FDA-Authorized Clinical Trials in Diabetic Patients With Open Wounds
- Lisofylline in Combination With Exendin-4 Reverses Diabetes in a Type 1 Model; LSF and GLP-1 Treatment Also Improved Islet Cell Viability and Normalized Insulin Secretion
- Metabolex Reports Positive Phase 1 Clinical Trial for Treatment of Type 2 Diabetes
 |
 |
User Comments (0)
RSS Feeds